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The current and preceding two centuries of medicine can be thought of as three separate ages; The Age of 
Amputation, The Age of Replacement and The Age of Regeneration. The field of medicine is only just 
starting to explore the possibilities of regrowth, whether it be missing limbs or degrading neurones. Stem 
cell research is still controversial but has some potentially exciting applications for future treatment. 
As it becomes possible to regrow missing body parts and replace failing ones, the life expectancy of 
people in developed countries may increase to previously unknown ages. However, simply replacing 
organs or body parts is unlikely to be the solution to fully unlocking the so-called ‘secrets of 
immortality’. To achieve this goal it is necessary to understand how the body ages and why it does so. 
5 
One of the foundations of research into aging is the study of telomeres, DNA repair mechanisms and their 
role in disease and cancer. In this thesis, recent research regarding telomeres will be reviewed. The effects 
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In the year 1860, a man crosses the street and his leg is crushed beneath the wheels of a wooden 
cart. He presents to his local physician with an open fracture of his tibia and is given a grave 
diagnosis; the leg must be amputated to prevent it becoming septic and risking the ill humour 
spreading to the rest of his body.  He will undergo surgery without anaesthetic or sterile 
conditions and, even if the amputation goes as smoothly as can be expected, he has a poor 
prognosis for the coming weeks. 
One hundred years later, in 1960, an elderly gentleman falls down some stairs and fractures his 
proximal femur. He is admitted to hospital and is kept comfortable with a femoral nerve block 
and opiate analgesics. In the morning, he is taken to a sterile operating theatre and rendered 
unconscious with a general anaesthetic before his fractured femoral neck and head are excised 
and replaced with a synthetic, metal and plastic prosthesis. His recovery is swift, although he is 
likely to need further surgery in future as the implant wears and begins to fail. 
A further fifty years later, in 2010, a man loses the tip of his small finger due to an accident with 
a sharp kitchen knife. Unable to reattach the tip, physicians try an experimental procedure to re-
grow the missing part of finger. They apply a powder, partially composed of pig bladder cells, 
and in several weeks time, report that he has re-grown the missing finger tip, complete with 
nail bed. He suffers no ill effects of the procedure and returns to his daily activities as usual, 
with a bit more care when using a sharp knife. 
These three stories give examples of generalised names that can be given to the current and 
preceding two centuries of medicine; The Age of Amputation, The Age of Replacement and The 
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Age of Regeneration. The field of medicine is only just starting to explore the possibilities of 
regrowth, whether it be missing limbs or degrading neurones. Stem cell research is still 
controversial but has some potentially exciting applications for future treatment. 
As it becomes possible to regrow missing body parts and replace failing ones, the life 
expectancy of people in developed countries may increase to previously unknown ages. 
However, simply replacing organs or body parts is unlikely to be the solution to fully unlocking 
the so-called ‘secrets of immortality’. To achieve this goal it is necessary to understand how the 
body ages and why it does so. 
The question of why our bodies decline when we age can be answered by thinking about our 
natural life span - the life expectancy of someone who lived in the Stone Age would be around 
35 to 40 years. The Theory of Evolution states that organisms evolve with the most energy 
efficient method of continued existence and function. Therefore, it would not be of benefit for 
an organism to waste the vast amounts of energy needed to continue mechanisms for 
maintenance and repair of a body past its expected life-span. Thus, humans have evolved with 
regenerative processes which keep our bodies healthy during our time maturing, mating and 
raising our offspring. When this job is done, the human body begins the slow decline that is 
associated with age, if other limiting factors have not played their part, such as disease, 
predation and injury. 
It is only by the intervention of modern science and medicine that we have extended this 
expected life-span and enter the time period where the body has not evolved protective 
mechanisms.  
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In the last century, the human life expectancy in developed countries has doubled, mainly due 
to improvements in sanitation and medical advances in neonatal care, infection control and 
treatment of cardiovascular and respiratory disease. The population of the world that is over 60 
years of age is expected to reach 1.2 billion by 2025. As medical professionals have to manage 
an increasing number of age-related diseases, it will become more critical to understand the 
science behind aging and how it relates to disease.  
One of the foundations of research into aging is the study of telomeres, DNA repair 
mechanisms and their role in disease and cancer. In this thesis, recent research regarding 
telomeres will be reviewed. 
As we enter the age of regeneration, new medical problems may present themselves, arising 
from the previously unknown effects of replacing diseased organs. It is still not known whether 
any detrimental effects will occur by taking a differentiated adult cell, such as an osteoblast, and 
forcing it to multiply many times to fill the required area of a new organ construct or area of 
tissue loss. The laboratory study carried out in this thesis aims to determine whether there is an 








Telomeres, Aging and Cancer
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Review of Literature Relating to Telomeres, Aging and Cancer. 
 
A review of current and recent research into the above topics was carried out with an emphasis 
on telomeres. Therefore the primary search term that was input into the boolean search was 
‘Telomeres’. This returned 56,047 results, which shows the intense interest that is currently 
invested in telomere research. For the purposes of this review, a more defined search was 
therefore required. Entering ‘Telomeres’ AND ‘Senescence’ returned 7,954 results, which was 
still a substantial number with a large percentage of results being of little relevance to this 
review. The addition of ‘Aging’ to the above terms lessened the results to 4,194, while adding 
‘Cancer’ lessened them to 1,307. Adding the two search terms together, making a search string 
of ‘Telomeres’ AND ‘Senescence’ AND ‘Aging’ AND ‘Cancer’, returned 642 papers that were 
highly relevant to the literature review. 
Further identification of important papers was possible by filtering for ‘most cited’, and recent 
developments identified by filtering by ‘date published’.
12 
Part 1.1  
Senescence 
The word senescence derives from the latin ‘senescere’, ‘to grow old’. When applied to a single 
cell, the term senescence refers to the process by which a cell ceases to be capable of 
reproduction or division. When applied on the level of the organism, the term refers to a long 
term, progressive reduction in the functional abilities of the organism to maintain tissue 
homeostasis and mount the necessary physiological response to stress. 
In humans, this decline in function correlates with many of the characteristic physiological 
changes associated with age, such as impaired wound healing, compromised immune response 
and muscle atrophy. 
The human body has a very high potential for replication and repair in response to stresses. 
This is achieved primarily by the undifferentiated stems cells in somatic tissues. This capacity 
varies with the tissue type and is highest in tissues with a high level of cell turnover, such as the 
gut or liver, as stem cells produce large numbers of specialised precursor cells. In lower turn-
over tissues, such as the heart and brain, there is a smaller reservoir of specialist stem cell 
progeny. 
The aforementioned age-related decline is partly a result of a decrease in the proliferative 
capacity and partly due to inappropriate differentiation of stem cells. In the musculoskeletal 
system, age-related decline includes osteopenia and sarcopenia, resulting in impaired mobility. 
There is also a reduction in the regenerative ability of muscle after injury, as myogenic fibres are 
replaced with fibrous tissue, rather than muscle tissue. The haemopoietic system has 
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decreased/altered cell lineages, resulting in a normocytic anaemia and impaired immune 
response, leading to decreased capacity to combat infection. The liver and kidneys are unable to 
process drugs and toxins as effectively. Lower turn-over organs, such as the brain, show a 
decrease in neurogenesis, meaning fewer new neurones are generated and there is an associated 
decline in function. 
Senescence begins in an organism after it is fully developed and consists of a decreasing ability 
to respond to stresses, diseases and physical demands, as well as an increase in age-related 
disease such as cancer. The chronological age of a mammal is not directly related to the degree 
of senescence displayed in their tissues, as there are a great many external and internal factors 
which can determine this. These include external factors, such as dietary intake and internal 
factors, such as reactive oxygen species and the diverse genetic phenotypes governing DNA 
repair1. 
Hayflick et al noted in experiments in the 1960s that cells appeared to have a limit to the 
number of times they were able to replicate in vitro2. After a certain number of replications, 
differing depending on the type of tissue and the organism it came from, the cells entered a 
state of irreversible growth arrest and could no longer be stimulated to divide. The cells 
continued their regular metabolic functions as normal but when their usual lifespan was 
complete they spontaneously died without division. Hayflick found this number to be around 
fifty divisions for human fibroblast cells. This maximum number of divisions, which seemed to 
restrict the replicative potential for certain lines of cells, was therefore named the Hayflick 
Limit. 
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Hayflick and Moorehead therefore hypothesised that there was an intracellular factor or 
messenger that was progressively lost with every cell division and was responsible for limiting 
the proliferation of the cell.  
The Hayflick Limit does not, however, apply to all cell lines. In certain tissues and types of cells, 
there exists no limit to the number of cells that may be produced. Cell lines with a high 
turnover due to their function, such as gut epithelial cells, have a much higher or non-existent 
limit. It has also been identified that in many tissues this limit does not exist until the organism 
reaches its maximum expected maturity and size. This is due to the necessity of organisms, such 
as humans, to grow from the two cells of sperm and egg into the many billions of cells present 
in an adult body. 
An important aspect of senescence is that although the cell is unable to divide, it still continues 
its normal cell cycle. This means that in vitro cells may remain viable indefinitely, in the absence 
of external influence. The situation in vivo is more complex as many factors can affect whether a 
cell continues to function or undergoes apoptosis. Examples of the two ends of the spectrum 
include senescent melanocytes of naevi, which can exist for years, and senescent tumour cells of 
liver carcinomas, which are rapidly removed by phagocytes3. 
This variation in replicative capacity also occurs between organisms of differing species. Small 
rodents such as mice have a much higher replicative capacity than humans while prokaryote 
organisms have an infinite capacity. 
The reasons for the Hayflick limit and its variations between tissues and organisms were not 
understood until the discovery of telomeres. Although telomere induced senescence appears to 
15 
be a very important factor in cellular senescence, there are many other causes for a cell to be 
driven into the permanently non-dividing state. These include many types of cellular stress and 
in the cancer suppression response in cells with activated oncogenes4.  
Non telomere-related senescence may be responsible for protection against melanoma. Pollock 
et al5 showed that most skin naevi have both a mutation of the BRAF oncogene and markers of 
cellular senescence6. However, they were not found to have shortened telomeres7. This indicates 




Part 1.2  
What are telomeres? 
The process by which a chromosome is replicated during cell division is an imperfect one.  As 
the single, long strand of DNA that comprises the chromosome is replicated, small numbers of 
base-pairs at its termini are unable to be transcribed, due to a failing in the process of 
replication known as the ‘end replication problem’.  
To understand this problem, it is necessary to look at the way in which chromosomes are 
replicated. Since a chromosome is comprised of two strands of DNA in a helical structure, the 
separate strands are identified by labelling their ends as either three prime (3’) or five prime 
(5’). The strands are arranged opposite one another so the 3’ end of one strand corresponds with 
the 5’ end of the other. With this labelling, it is possible to identify a strand by describing it as 
the 3’-to-5’ strand or the 5’-to-3’ strand. 
Synthesis of DNA uses enzymes called DNA polymerases which ‘move’ along the original piece 
of DNA, known as the template strand, in the direction of 3’ to 5’. The synthesis begins at many 
sites along the DNA, known as primer sites. At these sites, the template DNA separates its two 
strands to allow the polymerase to bind and initiate replication on both strands. Synthesis 
therefore occurs simultaneously at many sites and in both 3’-to-5’ and 5’-to-3’ directions, until 
the individual sections of replication meet. 
Synthesis is straightforward on the 3’ to 5’ template strand, as it is the direction the polymerase 
acts in, producing new DNA called the leading strand in a continuous, unbroken segment. 
However, problems arise with the 5’ to 3’ strand, as synthesis cannot be initiated at its termini. 
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This means that the process has to ‘wait’ until the template chromosome is ‘opened’ enough to 
allow synthesis to occur opposite to the direction of replication. Small sections of RNA attach to 
points on the template strand and act as primers to allow polymerase to start synthesis. The 
production of this DNA, known as the lagging strand, is therefore discontinuous, producing 
many small fragments of DNA, called Okazaki fragments. These are later ‘stitched’ together by 
DNA ligase and it is at this stage that the loss of base pairs occurs. DNA must be present in 
front of an RNA primer for DNA ligase to stitch the RNA in place. This occurs at the ends of all 
the Okazaki fragments but not at the end of the lagging strand, where an RNA primer sits on its 
own. The RNA is later degraded and therefore leaves a deficit of around 200 bases at the end of 
the lagging strand. This is often called the End Replication Problem. 
The end replication problem could be harmful to an organism if the DNA that was lost in 
replication was of importance to its survival. The ends of chromosomes are therefore protected 
by long segments of simple tandem DNA repeats that do not code for any gene product8, 
known as telomeres. This portion of chromosome is essentially ‘junk DNA’ as loss of any part of 
it does not affect the function or survival of the cell. 
Telomeres therefore act as protective ‘caps’ on the ends of the vital DNA, the centromere, and 
are sacrificed a few base pairs at a time to allow a perfect copy of the important chromosomal 
DNA to be produced. They can be thought of as similar to the plastic bands on the ends of a 
shoelace which are themselves worn by use, but protect the inner portion from fraying. 
The presence of telomeres on the termini of a chromosome also distinguishes its ends from 
unwanted breaks in the DNA. If DNA breaks are identified in a normal cell, cell cycle arrest 
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occurs and DNA repair mechanisms are activated or cell apoptosis occurs if damage is too 
great. Telomeres protect the chromosomes from incorrect activation of these mechanisms8. A 
minimum length of telomere is required for this function. 
Another vital function of telomeres is to limit the inevitable, inbuilt errors that occur during 
DNA replication. Transcription errors are more likely to occur at the ends of a sequence of DNA 
and so a non-vital buffer of repeating DNA at the chromosome termini allows these errors to 
occur harmlessly. 
Telomeres are also vital to avoid homologous recombination, where the ends of chromosomes 
attach to their other end and form a circle, and non-homologous end joining, where the ends 
attach to another chromosome entirely. This is a problem in eukaryotes as they have linear 
chromosomes with two ends, unlike the majority of prokaryotes whose chromosomes are 
circular, with no telomeres at all. 
Most eukaryotic telomeres consist of six to eight base-pair long repeats, containing mainly 
guanine.  In vertebrates, the telomeres are made up of a sequence of 6 bases, TTAGGG, 
repeating up to 2000 times.  
To counter this loss of telomere DNA, an enzyme called telomerase exists which can add repeat 
sequences to the 5’ end of a telomere. It consists of an RNA primer (AAUCCC ), which 
produces the TTAGGG repeat, and a protein called telomere reverse transcriptase, which 
catalyses the process9,10. This enzyme is normally only present with significant activity during 
embryogenesis and in certain adult cells, such as germ line cells11, but is thought to be highly 
active in a large proportion of cancer cells, which will be discussed later. Telomerase is active in 
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all adult tissues but its level of activity is so low as to have little or no effect on the progressive 
telomere attrition that occurs from replication.  
The importance of telomerase in maintaining telomere length for replicative capacity was 
highlighted in experiments using human fibroblasts12. In normal circumstances in vitro, the 
division of fibroblasts results in progressive telomere shortening and subsequent cellular 
senescence, once the Hayflick limit is reached. When a mutation that induces enforced 
expression of TERT (the catalytic subunit of telomerase) is introduced, the telomere length is 
stabilised and the cells have an unlimited replicative capacity, thus bypassing the Hayflick 
limit.  
The Hayflick limit therefore prevents the unchecked proliferation of normal non-cancerous cells 
but also, crucially, prevents the proliferation of pre-cancerous cells that are undergoing 
neoplastic change. This provides a major obstacle to tumours developing their characteristic 
malignant and infiltrative properties and almost all human cancers  have developed some way 




a) DNA is arranged in a double strand, opposite to one-another, with ends of each strand 
labelled 5-prime and 3-prime. 
b) When the ribosome binds to the DNA it separates the strands and, since it works from 5’ to 
3’, immediately begins synthesising RNA from the leading (blue) strand. 
c) When the ribosome ‘opens’ the DNA further, an RNA primer is encountered on the trailing 
strand and RNA synthesis can begin in the opposite direction to the leading strand. 
d) The ribosome encounters RNA primers intermittently along the length of the trailing strand 
so many small sections of RNA are synthesised, known as Okazaki fragments.
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Figure 1.2b 
e) An enzyme called DNA ligase binds to gaps between the Okazaki fragments in order to 
‘stitch’ them together into one long strand. 
f) This process requires DNA/RNA on both sides of the gap so no DNA ligase binds at the 5’ 
end of the trailing strand. 
g) As the DNA ligase does not bind at the end of the strand, the final base is not transcribed and 
hence is lost in the synthesis 
h) To combat this, chromosomes have telomere end-caps. This means that the DNA on the 
peripheries is expendable ‘junk’ and no important information is lost.
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Part 1.3  
The Role of Telomeres in Aging 
Experiments in the 1960s demonstrated a phenomenon of cells spontaneously entering a state of 
irreversible growth arrest2. As stated in the previous section, this state occurs after a finite 
number of cell divisions, known as replicative senescence or the Hayflick Limit, and is 
accelerated under certain conditions such as oxidative stress14,15. It was not until the discovery of 
telomeres in the 1990s that a reason for this senescence was understood12,16. 
Also, as discussed previously, small portions of telomere are lost with every cell replication, 
resulting in a reduction in the length of telomeres over time11. In humans, this appears to be 
around 40-100 base pairs of the terminal telomeric repeat DNA with every division. When the 
telomeres reach a critical length, they lose their protective capacity and senescence occurs. This 
is likely to be due to increased activity of the oncogene p53, identifying short telomeres as DNA 
damage and triggering senescence17. Senescence itself is when the cells enter a state of 
permanent growth arrest, meaning they can no longer divide, but are capable of continuing to 
be metabolic activity18. 
The idea that telomere length was responsible for replicative senescence was given further 
support when it was found that when telomerase was expressed in foreskin fibroblasts, 
replicative senescence was avoided entirely12.  
As humans become older, the number of times their cells have replicated increases. This means 
that the telomeres of cells that lack telomerase activity become shorter and closer to the critical 
length mentioned above. Human fibroblasts have a Hayflick limit of around 50-70 divisions11 
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but this varies for different cell types.  Some tissues display significant telomere shortening over 
time, such as peripheral blood cells and hepatocytes, but some show very little shortening at all, 
such as human brain tissue19  
Although telomeres are responsible for cellular senescence, it is still a matter of debate as to 
their role in organismal senescence17. However, it is widely viewed that telomeres and 
telomerase have a significant role in the formation and proliferation of cancerous cells. 
A possible role of cell senescence in organismal aging could be in accumulation of senescent 
cells and a decrease in the regenerative potential of the stem cell reservoir3. As a person gets 
older, the number of senescent cells in their tissues increases, possibly reaching a level which 
compromises the tissue’s overall ability to respond to stresses. Aging could be produced by 
either this accumulation of senescent cells or by the exhaustion of the regenerative potential of 
stem cells.  
Compared to humans, mice have a significantly shorter lifespan but, despite this, have a high 
incidence of cancer. They also have much longer telomeres and a high activity of telomerase17. 
When telomerase activity is suppressed in knock-out studies in mice, an increase in cancer 
resistance is found. Conversely, when over-expression of telomerase is achieved, a relative 
increase in cancer incidence is found20. A similar relationship seems to exist with expression of 
the p53 oncogene. As discussed previously, the p53 gene is likely to be responsible for inducing 
senescence in the presence of DNA damage. Mice that lack p53 have an increased cancer 
incidence and those with an over-expression of the gene are short-lived but cancer resistant21. 
Senescence therefore seems to be a tumour suppressor mechanism controlled largely by 
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telomere length, telomerase activity and the p53 gene. Large animals have a higher number of 
cells and hence a greater number of targets for cancerous change. This means that they benefit 
from telomerase suppression with a greater cancer resistance but at a price of age-related 
changes. Smaller animals, such as rodents, benefit from high telomerase activity but have high 
predation rates in the wild so are not adversely affected by the associated increase in cancer 
incidence21. 
Studies on cancer resistant mice have shown that telomerase activity and telomere length have 
a direct effect on lifespan and physiological age. Mice with an over-expression of TERT, the 
catalytic subunit of telomerase, had a higher median lifespan and a physiological appearance 
characteristic of a younger mouse, with increased epidermal thickness, higher epidermal stem 
cell proliferative function and decreased associated gastric and dermatological disease22. 
Comparisons between mice with naturally occurring long and short telomeres have shown 
differences in functional decline in the presence of TERT over-expression. Over-expression in 
mice with long telomeres results in a prevention of age-related functional decline, while in mice 
with short telomeres, a decline occurs in highly regenerative organs such as the intestine, testes 
and haematopoietic system23. 
Human studies into telomere length and aging have been carried out by identifying progeroid 
syndromes which induce premature aging. These include Werner syndrome, ataxia 
telangiectasia and dyskeratosis congenita. 
Werner syndrome is rare autosomal recessive disorder, caused by a mutation in the WRN gene, 
on chromosome 8, which is involved in DNA repair and telomere maintenance. This mutation 
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also results in a failure to control DNA recombination and chromosome aberrations, causing 
genome instability. The reduced capacity for telomere maintenance results in rapid telomere 
attrition and premature senescence, as demonstrated in fibroblasts of Werner’s sufferers24. The 
role of telomere shortening in the causation of senescence is shown by the fact that premature 
senescence can be avoided in vitro by enforced TERT expression.  
Patients with Werner’s have no physiological differences until puberty, when they cease normal 
growth and begin to exhibit a series of multi-organ, progressive pathologies that are normally 
associated with age. These include senile cataracts, osteoporosis, skin atrophy, heart disease and 
cancer, leading to a significantly decreased median life expectancy of 47-48 years23. 
Ataxia telangiectasia is also an autosomal recessive disorder, characterised by cerebellar 
degeneration, skin abnormalities and multiple malignant neoplasms. It is caused by mutations 
in the ATM (Ataxia Telangiectasia Mutated) gene, resulting in abnormalities of DNA damage-
signaling/repair and telomere maintenance. As with Werner’s cells, premature senescence can 
be avoided in vitro by enforced TERT expression24. 
The relevance of telomerase in the process of aging has been investigated extensively with the 
use of telomerase knock-out mice. These mice had TERC (Telomerase RNA Component) gene 
deletions which prevent the expression of telomerase. First generation TERC knock-out mice 
showed very little phenotypical difference to control mice, only showing only modest stem cell 
dysfunction in highly proliferative organs and having a near-normal lifespan. This was thought 
to be due to the naturally long length of telomeres, thus allowing a telomere reserve that 
retained end-capping. However, in the subsequent generations of knock-out mice, 
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progressively worsening telomere dysfunction was noted, with the associated shortened 
lifespan and widespread, premature age-characteristic tissue degeneration25. The degree and 
severity of these premature degenerative changes could be directly correlated with the degree 




Telomeres and Cancer 
In experiments in vivo, the process of telomere dysfunction-based senescence, that leads to 
cellular senescence and cessation of growth, requires several cell cycle checkpoints6. Most 
importantly, these require the correct functioning of the previously mentioned p53 pathway 
and the pRB pathway. When these pathways are intact, telomere shortening leads to permanent 
growth arrest and eventually apoptosis. 
 
If the above processes are interrupted, telomeres continue to shorten and become progressively 
dysfunctional. Instead of the normal process of telomere dysfunction-based senescence, the 
unprotected, dysfunctional telomeres cause the cell to enter a state called telomere-based crisis26. 
Although crisis and senescence both result from shortening of telomeres, crisis differs in that 
the cell does not enter the characteristic cessation of growth and DNA synthesis. Instead, the 
short telomeres cause end-to-end fusions of chromosomes, resulting in mitotic catastrophe, 
multipolar cell division and gross aberrations in chromosome number6. The oncogenic 
mechanisms which interrupt the cell cycle checkpoints allow the cell to bypass normal 
senescence and avoid apoptosis.  
Although a cell in crisis does not undergo normal cycle arrest and apoptosis, evidence suggests 
that it can still be a cancer-preventative mechanism. To convert normal human cells to a 
tumourigenic state, experiments have used SV40 T (a DNA virus which binds to, and 
inactivates, p53 and pRB) and Ras (a GTPase signal transduction protein which causes cells to 
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develop malignant properties such as invasiveness and proliferation)6,27. In these experiments, 
the resultant tumours grew in size but the cells subsequently entered crisis. Further 
proliferation when transferred to a different host did not occur, even when rescue from crisis 
was attempted by activation of telomerase28.  
Formation of anaphase bridges has been used as a marker of telomere dysfunction29. Most 
human cancers have cells containing anaphase bridges but some normal, non-neoplastic cells 
also contain low numbers, with an inverse relationship between frequency of anaphase bridges 
and telomere length30,31. The fact that active normal cells show signs of telomere dysfunction 
without senescence suggest that telomere-based crisis may be a secondary protective measure 
which limits cancerous growth when telomere dysfunction-based senescence fails. 
It is only when cancerous cells mutate to the point where telomerase expression is high enough 
to prevent telomere dysfunction, that the cell can bypass crisis and replicate without limit. This 
can happen by mutations or by activation of oncogenes such as c-Myc32. 
 
When compared to other organisms, such as rodents, humans have relatively short telomeres. 
Telomerase activity is also minimal in the majority of human cells, resulting in a progressive 
shortening of length with each cell division. The only cells which show a higher telomerase 
activity are stem cells, and even these do not have a high enough level to continue activity in 
the cells that they differentiate into.  
This lack of telomerase activity and the relatively short length of telomeres is an important 
cancer-suppression mechanism. Shortened, dysfunctional telomeres cause inhibition of 
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tumourigenesis by either telomere dysfunction-related senescence or telomere-based crisis, 
meaning the growth of a potentially lethal cancer is suppressed as unchecked cell division 
results in senescence or crisis. This occurs in cells which are pre-cancerous unless there is an 
oncogenic mutation.  
The reason why a replicative limit is tumour protective lies in the fact that a cell must undergo 
multiple mutations for it to become malignant33. When a pre-malignant mutation occurs, a cell 
must divide at least 20 times before the population of mutant cells reaches a level where a 
second mutation is likely to occur. As most mutations occur as a single allele, they are recessive 
and hence require a further 20 or so division for elimination of the native allele and 
homogeneity to occur. The homgenous mutant cells would then need a further 20 divisions for 
the population to expand again. 
This process requires a great number of divisions for malignancy to occur. The result of this is 
that most pre-malignant cells reach the Hayflick limit with only 1 or 2 mutations, undergo 
senescence and hence do not progress to cancer34. A method to bypass this limit is therefore 
present in more than 90% of human cancers, namely telomerase up-regulation, as previously 
discussed. By extending its proliferative life-span, a mutant cell line is given the time for 
oncogenic mutations to accumulate. 
If prevention of cancer by replicative limit is so effective, then why is the limit as high as 50 
divisions? The reason is that, although a very low replicative limit would prevent almost all 
cancerous changes, it would impair the function of the organism in general. The process has 
therefore evolved as a balance between cancer suppression and allowing cells sufficient 
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proliferative capacity for growth, maintenance and repair, over the expected life-time of the 
organism. 
What then, are the advantages of having long telomeres and active telomerase in animals with 
short life-spans? Small animals that have high predation rates are, firstly, more likely to suffer 
an incapacitating injury. If this injury is not rapidly repaired then the animal will quickly be 
picked out by a predator and eaten. Therefore the extensive proliferative abilities associated 
with telomerase activity are beneficial in early healing and return to function.  
The triple-G sequences in telomeres are also a preferred site for oxidative damage35. If an 
organism has very long telomeres, the repetition of the triple-G sequence every six base pairs 
means that oxidation is much more likely to occur harmlessly here, rather than at an important 
site in the genomic DNA. 
 
Many of the premature aging diseases mentioned previously have a defect in the DNA repair 
mechanism which results in a loss of genome integrity. The role of the tumour suppressor gene 
p53 can be highlighted by the fact that, in mice bred with similar DNA repair mechanism 
defects, the p53 response to DNA damage and subsequent degenerative aging is almost 
completely reversed when p53 is deleted23. 
The p53 tumour suppressor has been called the guardian of the genome as it is the main cellular 
mechanism to initiate apoptosis and growth arrest in response to genotoxic stresses. These 
stresses include not only DNA damage and telomere dysfunction, but also UV radiation, 
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reactive oxygen species and hypoxia. It is also not limited to initiating cell apoptosis but is 
responsible for signalling DNA repair pathways, depending on the severity of the stress. 
Deletion of p53 in mice with critically short telomeres, who would otherwise show signs of 
premature aging, results in a decrease in apoptosis and an increase in proliferation, evidenced 
by decreased organ dysfunction in highly proliferative tissues. Further, late generation 
telomerase knock-out mice, such as those discussed previously, have similar phenotypes to 
wild mice when the p53 gene is also knocked-out as the cellular senescence and apoptosis 
pathways are no longer initiated in response to telomere dysfunction.  
The increase in stem cell function when p53 is deleted in mice with short telomeres does not 
result in an increase in mean life-span. This is because the cells lose their tumour suppression 
and the mice have a much higher incidence of cancer36. The types of cancer that are caused in 
telomere dysfunctional mice with knock-out p53 and TERC are similar to the spectrum that 
affects elderly humans, mainly epithelial cancers of the skin, GI tract and breast36. 
The role of p53 in both cancer and aging has also been shown at the opposite end of the 
spectrum; in mice which have been engineered with hyperactive p53. These mice develop 
phenotypes of premature aging but are cancer resistant, showing increased numbers of 
senescent cells in all tissues37. 
Following on from the research carried out on knock-out mice, human cell studies have 
confirmed the role of telomere dysfunction and telomerase in cancer; ie. that programmed 
telomere shortening, resulting in senescence, is an important system for tumour suppression. 
Support for this can be evident as most human cancers negate the shortening of telomeres 
32 
through increased expression of telomerase. When telomerase is inhibited in already cancerous 
cells, they regress to pre-cancerous rates of telomere shortening and senescence.  
As has been mentioned previously, humans and mice have differing requirements for tumour 
suppression, due to their life-spans and opposite ends of the food-chain. The lifetime risk of 
cancer can be thought of as proportional to the size of an organism (ie. the number of cells it 
contains and hence the number of sites for mutation to occur) and its average lifespan (the 
length of time a cell line has for mutations to occur)34. A 70kg human with a life expectancy of 70 
years should therefore require 125,000 times the cancer resistance of a 20g mouse that lives for 2 
years38.  
This means that mice cells do not need to regulate their tumour burden through telomere 
attrition, instead gaining the benefits of unlimited proliferation and long telomeres. Humans, 
however, benefit from the the tumour suppressive advantages of senescence. Therefore human 
cells employ multiple pathways to activate senescence in response to telomere dysfunction. 
This can be shown in experiments with human cell cultures which have either the p53 or Rb 
pathways inhibited39. If p53 activity is suppressed, the cell cultures gain a small number of extra 
cell divisions but eventually the dysfunctional telomeres trigger senescence by inhibiting 
phosphorylation of Rb. Conversely, if the Rb pathway is interrupted, the p53 pathway can 
enforce senescence.  
Multiple mechanisms for triggering senescence, even in the absence of one or more pathways, 








Limb lengthening is a procedure used to lengthen or correct deformities of long bones. It was 
first described in 1905 by Codivilla, an Italian surgeon, and later refined by Ilizarov, who 
described distraction osteogenesis. The process involves division (osteotomy) of the target bone 
and fixation with a distraction device which can separate the ends of the osteotomy gradually 
over several weeks. As the bone ends are slowly pulled apart, new bone tissue is formed 
between them. Once the desired length is reached, the new bone is allowed to heal in a 
consolidation phase before the fixator is removed. This consolidation phase can take three to 
four times the length of time of the distraction phase, which itself can take a month per 
centimetre of new bone. 
The procedure has traditionally used the Ilizarov apparatus, an external fixator device. This 
consists of a series of rings which surround the bone, above and below the osteotomy site. The 
rings are fixed to the bone with percutaneous pins and tensioned wires and to one another with 
rigid struts. The struts which span the osteotomy site have a screw system incorporated so as to 
allow a gradual extension of their length, whilst providing a stable construct. Once in place, the 
screws are turned to distract the bone. 
The optimum rate of distraction has been found to be around 1mm per day. Studies by Ilizarov 
in the 1980s40 experimented with various factors affecting the quality and success of distraction. 
Canine tibia were subjected to a limb lengthening procedure with both open osteotomy and 
closed osteoclasis. The speed at which the distraction was carried out, measured in millimetres 
per day, and the incrementes of distractions per day were varied.  
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Ilizarov found that premature consolidation occurred when the distraction rate was 0.5mm per 
day. In these dogs, there was dense bone regeneration at the osteotomy sites which 
consolidated by only 23 days into distraction, preventing further lengthening and resulting in 
traction fractures at the interface between original and new bone. In those dogs that had a 
distraction rate of 2mm per day, the space between the bone ends was filled with dense fibrous 
tissue but no evidence of osteogenic activity.  
The balance between early consolidation and fibrous infiltration was found to be at 1mm per 
day. However, this rate still had variations in quality, as measured by observing osteogenic 
activity with histological staining, depending on the number of steps of distraction in a day. 
Similar results to the 2mm per day group were found when the distraction was done in a single 
step every 24 hours. The best outcome was found by carrying out the distraction of 1mm in 60 
steps through a 24 hour period, with a formation of cortex that was ‘almost identical to the 
original bone thickness and density’. 
This difference in quality of bone formation depending on distraction frequency is an important 
limiting factor in the use of Ilizarov frames. Difficulties arise when trying to increase the 
distraction frequency, as the process of tightening screws around the frame can be complex. 
However, many patients are able to cope with four-times daily distractions. The advent of self-
lengthening intra-medullary devices, as mentioned below, combat this difficulty to some extent 
and allow for a higher frequency of distraction. This occurs in very small increments, either 
automatically or by utilising the normal movement of a joint to activate the lengthening. 
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Additionally, in the above experiment, all of the open osteotomy sites showed some evidence of 
fibrous infiltration at all stages of the distraction, whereas only a limited number of the closed 
osteoclasis sites exhibited this.  
Although external fixators have proven effective in distraction procedures, they have significant 
co-morbidities and impact on a patient’s quality of life. Pain, pin site infections and hardware 
failure are common and the fixator itself is large and bulky. The frames are usually required for 
long periods of time, from many months to over a year. They cause problems with clothing, 
mobility and have psychological implications as patients are very conscious of their presence. 
In recent years, internal fixation devices, called intra-medullary skeletal kinetic distractors, have 
been developed in attempts to address some of the complications of external fixators. These 
devices are intra-medullary nails that telescope to the desired length either mechanically by a 
specific movement at the ankle (such as orthofix) or by a radio signal activating an electric 
motor (such as fitbone). 
Studies by Cole et al41 in the late 80s investigated the clinical outcomes of ISKDs, with 
favourable results. They carried out lengthening procedures on femurs and tibias, in patients 
who had suffered trauma, infection, polio and burns, all with a subsequent limb length-
discrepancy. All patients in the study eventually went on to union, even with lengthenings of 
up to 110mm. The only complications they found in this study was implant failure, which was 
corrected in subsequent cases by a design change. They concluded that the ISKD represented a 
safe and cost-effective option that ‘reduces lifestyle disruption and complications’. 
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Later studies have not been so favourable42,43, with new complications occurring when compared 
to external fixators. They found that, although fixator-induced morbidity can be reduced with 
ISKDs, there are complications associated with nail guidance and operative technique. A 
maximum distraction of perhaps 4cm for the tibia and 8cm for the femur has been suggested 
when using an ISKD42 in order to limit weak consolidation and contractures. This means that if 
greater distraction distances are needed then multiple ISKDs can be used in sequential nail 
exchange operations. Binding of bone regenerate at the osteotomy site was also noted as a 
complication43, leading to failure of lengthening and a need for re-osteotomisation.  
Cosmetically, patients often have a better outcome with ISKDs compared to external fixators, as 
they have no visible external sign of the device during the distraction process and there is less 
scarring when the process is finished. 
Distraction osteogenesis has mainly been used after trauma, such as when a fracture occurs at 
the epiphyseal plate or after bone loss, but can also be used to correct congenital and 
developmental deformities, such as congenital short femur and rickets. New bone can also be 
grown following resection of neoplastic disease, such as osteosarcoma, or bone destruction in 
osteomyelitis. 
Distraction osteogenesis has been shown to be effective in treating non-unions with bone loss44. 
Historically, tibial non-unions were difficult to treat due to their associated complications of 
deformity, chronic osteomyelitis and length-discrepancies. Often it was difficult to treat these, 
even with bone grafting and rigid internal fixation, resulting in a need for amputation. As 
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Ilizarov frames and distraction procedures were developed, these problems could be effectively 
addressed. 
Recently, correction of deformity has been facilitated with the use of hexipod devices, such as 
the Taylor-Spacial Frame. This is a ring-structure external fixator with six calibrated telescoping 
struts ‘zig-zagging’ between the rings either side of the deformity. Prior to these frames, it was 
difficult to correct deformities accurately as they often occur in multiple planes, making simple 
hinged distraction devices insufficient to correct anatomically.  
The process of distraction creates an area of new bone to form and fill the gap created between 
the original bone ends. This tissue is formed by cells at the ends of the osteotomy dividing and 
proliferating at a greatly increased rate than would normally be required. This could have 
profound effects on the telomere length and increase the risk of malignant transformation or 
senescence in the cells. The aim of this study is to identify if this increased rate of division 
results in a decreased average length of telomere in the cells of the newly formed tissue. If this 
were the case, the reduction in telomere length would have implications for neoplastic change 
in the new tissue. This would be especially important since, in some patients, the procedure is 






Changes in Telomere Length in Rabbit 





In rabbit tibias subject to distraction osteogenesis, the increased cell turnover at the site of new 
bone formation causes an artificial reduction in telomere length in osteoblasts due to replicative 




Reasons for Research 
Following injury, the normal response of bone healing follows a well established pattern of 
reaction, repair and remodelling. Initially, blood collects around a fracture site and forms a 
haematoma which organises with the proliferation of fibroblasts. These fibroblasts are 
responsible for the formation of granulation tissue. After a few days, cells from the periosteum 
develop into chondroblasts and osteoblasts. These cells make the fracture callus (composed of 
hyaline cartilage and woven bone) which is a stable but mechanically weak construct. 
Following this, the newly formed cartilage and woven bone are gradually replaced by lamellar 
bone and later remodelled by osteoclasts/osteoblasts over a course of years into compact bone. 
The healing process outlined above normally occurs over relatively short distances, requiring 
bone ends in a fracture to be within a few milimetres of one another. If greater distances occur, 
then the bone will fail to unite and instead will either form atrophic bone ends or progress to 
fibrous interposition/non-union. 
When a bone is subjected to a distraction procedure, the two ends of the fracture or osteotomy 
are first placed in direct contact so as to allow the normal healing process to begin. However, 
before the consolidation phase is reached, the fracture callus is pulled apart, increasing the 
distance between the original bone ends. This induces the cells of the callus in between the bone 
ends to proliferate to fill the gap that forms. 
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The osteoblasts themselves may be forced to replicate many times, potentially reaching their 
replicative limit early. It may also be the case that the pool of stem cells in the tissue that 
osteoblasts arise from may be prematurely exhausted or brought close to depletion. 
This study is therefore aimed at identifying whether there is a measureable difference in the 
physiological/replicative age of osteoblasts in bone subjected to a distraction. This is measured 
by comparing the length of telomeres from osteoblast at various points in the distraction, at 
either end of the distraction site and from control sites of bone on the contralateral side. 
The bone first needs to be demineralised to allow processing in a DNA isolation pathway, 
before carrying out a telomere detection assay. The overall physiological age of the tissue was to 
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This was carried out on a total of 6 rabbits by Professor Simpson. Under anaesthetic, each rabbit 
had an osteotomy performed on a single tibia and two screw-pins inserted at either side of the 
osteotomy. A distraction frame was then applied to the 
pins. After the period of callus formation (approximately 1 
week) the distraction process was started. This required 
increasing the gap between the pins by 0.7mm per day for 
a period of 10 days, resulting in a total distraction of 30mm. 
 
 
Identification of Suitable Bone Growth 
A period of 6 weeks was then left to allow for consolidation 
and following this, the quality of the bone between the 
osteotomy sites was assessed using radiographs. At this 
stage there was only one animal with sufficient bone 
growth to allow for measurement. This animal was then 
humanely killed in accordance with animal handling 
protocols. One other animal had poor to moderate bone 
growth and had samples harvested for analysis to check 
that the procedure was viable. 
A further three rabbits had distraction procedures carried out at a later date to provide more 
samples for analysis. 

























a) Ex-fix applied 
b) Osteotomy made 
c) Distraction at 1mm/day 
d) Consolidation phase once 




Harvesting of Bone Samples 
Both lower limbs of the rabbits were harvested and fresh frozen directly following death. These 
were kept at -40℃ in the university tissue storage unit. At the time of harvesting, the samples 
were removed from the freezer and prepared once thawed to room temperature. 
All soft tissues were 
stripped from the tibia 
and the bone marrow 
was removed. This was 
carried out with 
scalpels, bone 
‘nibblers’ and 
curettage. At this stage 
the importance of good 
quality bone 
consolidation was 
identified as the poor 
quality samples proved 
difficult to prepare. In 
these samples, there was a lot of fibrous tissue ingrowth into the callus and between the bone 
ends which made differentiation between suitable sample tissue and unwanted soft-tissue 

























a) Centre of regenerate identified and 4mm sample taken, with 
adjacent samples 
b) Bone cleared of soft tissue and morselised 
c) Fragments placed in grinder with liquid nitrogen 
d) Grinding repeated until powder homogenous 
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problematic, although this immature distraction osteogenesis material should have theoretically 
undergone the same number of cell divisions. 
Sandpaper was used as a final step in removing all soft tissues from the bone sample. 
The contralateral tibia to the distracted one was also stripped and prepared to provide a control 
sample for comparison and standardisation in each animal. 
 
Once stripped of soft tissue, the new bone between the osteotomy ends was identified. This area 
of bone was cut into 3 samples of 3-4mm each, using a fine-bladed bone-saw. A further 2 
samples were taken from either side of this and a 1cm sample of bone from the same level on 
the contralateral tibia was taken as a control. 
 
Decalcification of Compact Bone 
The protocol used to isolate genomic DNA does not allow for samples from bone in its standard 
form. A technique for decalcifying the bone was therefore used which allowed the processed 
bone to be treated as a tissue sample, for the purposes of lysis and isolation. 
Following soft tissue stripping, each sample of bone was morsellised into as small pieces as 
possible, using bone nibblers. 
At this stage, the bone was still in pieces of around 2-3mm in size and the decalcification 
required the bone to be in as fine a powder as possible. The samples were therefore ground to 
powder using a metal blender. 
The morsellised bone samples were placed into the chamber of a 1cm wide metal blender and 
covered in liquid nitrogen, up to half the volume of the blender. The metal ball bearing was 
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then placed in the blender and the top securely screwed in place. Next, the blender was fixed 
onto a single-plane vibration ‘shaker’ and run at high speed for 1 minute. This caused the ball in 
the blender to oscillate at high speed and pulverise the frozen bone pieces. 
Following each step in the shaker, the bone was emptied from the blender and examined for 
consistency/particle size. On average the bone samples needed five repetitions of the blending 
process to obtain a homogenous powder that would be suitable for the decalcification process. 
The decalcification protocol that was used was designed for 5g of bone but, due to the small 
size of the samples, a maximum of 1.5g of bone powder was obtained. This meant that all 
measurements in the procedure were reduced to one quarter of their given value. 
Between 1g and 1.5g of each sample of bone from each animal was placed in individually 
labelled, 50ml sterile polypropylene tubes along with 10ml of 0.5 M EDTA at pH 7.5. This was 
the agent used for decalcification. Following this, the samples were agitated on a rotator at 40℃ 
for 24 hours. 
After agitation, the samples were centrifuged at 2000 x g for 15 minutes and the resulting 
supernatant was discarded. A further 10ml of 0.5 M EDTA was then added and the samples 
returned to the rotator for 24 hours. This was repeated to allow for full decalcification which 
was monitored by adding a saturated solution of ammonium oxalate, at a pH of 3.0, to the 
supernatant and assessing the resulting colour. If the solution remained clear then the process 
was complete. 
This was the most time consuming part of this step as a total of four to five repetitions were 
needed for complete decalcification, meaning a period of three to four days. 
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Once decalcification was complete, each sample was centrifuged as above but no further EDTA 
was added. Instead, the pellets in the polypropylene tubes were washed with 10ml of sterile de-
ionised water to remove ions that had accumulated during decalcification. The samples were 
then centrifuged again at 2000 x g for 15 minutes and the supernatant discarded. This washing 
procedure was repeated a further three times. The pellets were then stored in the -60℃ freezer 
prior to DNA isolation. The final step before isolation was to add 80µl of buffer ATL from the 
Qiagen QIAamp DNA Mini Kit to the still frozen samples. 
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Isolation of Genomic DNA 
The QIAamp Tissue DNA Mini Kit was chosen as the method for DNA isolation as it uses 
gravity-flow, which allowed the processing of multiple samples in parallel is possible. The  
process for each sample took approximately 3 hours. 
The genomic tips used in the kit required a specific weight of sample as it was possible to 
overload the tips and clog the filters. This was not much of a concern during the procedure as 
only small volumes of sample were obtained and were suitable for the smallest genomic tip 
size.  
The isolation procedure consisted of five stages;  
i)          Lysis and digestion with protease 
ii)  DNA binding 
iii) Washing 
iv) Elution  
v)  Precipitation.  
For digestion, proteinase K was chosen due to its stability and suitability for short digestion 
times. It is a protease isolated from the fungus Tritirachium album. At binding, the lysate was 
added to the genomic tips and the DNA bound to the filter, with degraded RNA, cellular 
proteins and metabolites passing through to the supernatant. The genomic tip was then washed 
with several different buffers to remove residual contaminants. The final stages involve elution 
of the DNA and precipitation in isopropanol. It was then suitable for Southern blot analysis. 
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Lysis and Digestion with Protease. 
This step caused lysis of the cell nuclei and denatured proteins to strip the DNA of all bound 
proteins. 
A combination of Buffer G2 and the RNase A stock solution (provided with the kit) was made 
by adding 4µl of RNase to 2ml Buffer G2.  
Each numbered sample of powdered bone was placed into a new 10ml screw-cap tube along 
with 2ml of Buffer G2 (plus RNase) and 0.1ml Proteinase K. 
The tubes were then incubated in a 50℃ water-bath for 3 hours. 




For each sample, a genomic-tip (Quiagen genomic-tip 20/G) was equilibrated by adding 1ml of 
Buffer QBT to it and allowing it to pass through by gravity, into a waste tray.  
Each sample of lysate was then centrifuged on full power for 10 seconds to reduce further the 
amount of particulate material. The clear precipitate was added to the equilibrated genomic-tips 
promptly. 
The samples were allowed to pass through by gravity. 
 
Washing and Elution 
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The genomic-tips were then placed over a clean 10ml collection tube and washed using 1ml of 
Buffer QC under gravity flow. This process was repeated 3 times to ensure all contaminants 
were removed. 
The genomic-tips were placed over a clean 10ml collection tube and 1ml of Buffer QF was 
added and passed by gravity flow. This step was repeated twice. 
 
Precipitation 
The tips were then placed over the final clean 10ml collection tube, which collected the 
processed DNA. The protocol that was used was designed for obtaining around 1ml of DNA 
but it was predicted that only 500µl would be possible from this process. All other steps prior to 
this used the volumes of buffer for 1ml of DNA but this step halved the volume of isopropranol 
for precipitation, to allow for greater concentration of DNA at the end. Thus 750µl of 
isopropranol was used, rather than 1.4ml. 
The 750µl of isopropranol was added to the genomic-tip and it was immediately placed, with 
the collection tube in a centrifuge for 15 minutes at 8000G at 4℃. 
The supernatant was then carefully removed, leaving a pellet at the bottom of the collection 
tube. 
 
This pellet of DNA was then washed further by adding 1ml of 70% Ethanol at 4℃, to remove 
precipitated salt. This was vortexed for 3 seconds to mix and then centrifuged for 10 minutes at 
5000G at 4℃. 
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The supernatant was again removed carefully with a pipette and the pellet was allowed to air 
dry for 5 minutes.  
The pellet was resuspended in 50µl of Buffer TE at pH 8 as it dissolves best in slightly alkaline 




Measurement of DNA Yield 
At the end of the DNA Isolation process the yield of DNA was determined for each sample 
from the concentration of DNA measured by absorption at 260nm on a spectrophotometer. This 
was expected to be between 0.1 to 1.0 for the next step to be accurate so each sample was 
diluted to the same concentration. The purity of the DNA was also assessed by a ratio of 
absorbance at 260 to 280 nm (A260/A280). Pure DNA has a ratio of between 1.7-1.9. The 




Telomere Length Assay 
A number of methods have been described to detect and measure telomere length. The method 
used here is the current standard. The TeloTAGGG Telomere Length Assay from Roche was 
used in this instance. This process utilises three main steps;  
 
1) Digestion of genomic DNA 
2) Separation of DNA fragments and Southern blotting 
3) Hybridisation, incubation and chemiluminescence detection 
 
Handling of all collection tubes during this process was carried out on ice. 
 
 
Digestion of Genomic DNA 
Following the steps described previously, the purified genomic DNA was digested by a mixture 
of frequently cutting restriction enzymes which do not cut telomeric DNA. The non-telomeric-
DNA was digested to low molecular-weight fragments. 
 
The genomic DNA was centrifuged at maximum speed for 5 minutes and the supernatant was 
placed in a fresh collection tube.  
A digesting enzyme mixture was prepared by mixing the enzymes Hinf I and Rsa I together in 
a 1:1 ratio, with a resulting concentration of 20 U/µl for each enzyme. 1µl of this mixture was 
required for each individual sample. 
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The next step required that each sample and the control DNA (provide with the assay kit) be 
diluted to a volume of 17µl. Therefore, 15µl of control DNA (1.5µg) was added to 2µl of 
nuclease-free water. 1.5µg of each sample DNA was added to nuclease free water to achieve a 
final volume of 17µl.  
2µl of digestion buffer 10x and 1µl of the enzyme mixture was added to each sample and mixed 
with pulse vortex for 5 seconds. 
The reaction mixture was then incubated for 2hrs at 37℃. 
The digestion reaction was then halted by the addition of 5µl of gel electrophoresis loading 




Separation of DNA Fragments 
The separation of DNA fragments was achieved using standard gel electrophoresis. 
A 0.8% highly pure, nucleic acid grade agarose gel 15cm in length was prepared and placed in 
TAE buffer. 4µl DIG molecular weight 
marker, 12µl nuclease-free-water and 
4µl 5x loading buffer was mixed in a 
reaction vial and vortexed.  
2µl of each DNA sample, at equalised 
concentrations, was then placed in 
each lane. 10µl of the diluted DIG 
molecular marker was then placed in 
each of the lanes at the far sides of the 
gel, to allow for accurate length 
measurement.  
The gel was then run at 5V/cm in 1x 
TAE buffer for around 3 hours, until 
the blue marker has migrated around 
10cm down the gel. 
Once gel electrophoresis was complete, the Southern transfer of the DNA was performed in 
standard fashion, with a positively charged nylon membrane. The gel was first submerged in 
HCl solution and agitated for 10 minutes at room temperature. This caused the blue tracking 






















a) Samples individually pipetted into wells and current 
passed through gel 
b) Larger fragments of DNA pass slowly through the gel 
while smaller fragments pass faster, reaching further 
from the wells. 
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dye to turn yellow. Next, the gel was washed with de-ionised water and submerged in 
denaturation solution for 15 minutes. This step was repeated and then the gel was submerged 
in the neutralisation solution for 2 periods of 15 minutes. 
Once the gel had been washed, it was placed in the Southern blotting apparatus and left to 
transfer for approximately 6 hours, or 
overnight. Following blotting, the 
DNA was fixed to the membrane by 
UV cross-linking and washed twice 





35ml of DIG Easy Hyb solution was 
pre-heated to 42℃ and the blotting 
membrane was agitated in 18ml of 
this solution for 40 minutes, whilst the temperature was maintained at 42℃. 
The hybridisation solution was prepared by adding 1µl of telomere probe to 5ml of the DIG 
Easy Hyb solution. The membrane was then transferred straight into the hybridisation solution 
and incubated/agitated for 3 hours at 42℃ 














b) Buffer solution 
c) Plastic block 
d) Filter paper 
e) Absorptive paper towel 
f) Filter paper 
g) Nylon Membrane 
h) Agarose gel  
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Following hybridisation, the membrane was washed with the stringent washing buffer I by 
agitation for 5 minutes. This was repeated with fresh buffer and then washed twice with 
stringent washing buffer II for 5 minutes, agitated at 50℃. 
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Chemoluminescence Detection 
The membrane was once again washed with 200ml of 1x washing buffer and then placed in 
100ml blocking buffer, to be incubated/agitated for 30 minutes at room temperature. 
Next the membrane was 
incubated in Anti-DIG-AP 
working solution for 30 
minutes as above. It was then 
washed twice with 100ml 1x 
washing buffer. 
Finally, the membrane was 
incubated with 100ml of 1x 
detection buffer for 5 minutes 
at room temperature. The 
membrane was then removed 
from the buffer and placed 
onto an absorbant sheet of 
paper, but not allowed to dry. 
Instead it was quickly placed 
into a hybridisation bag, 
DNA side up. 40 drops of 
substrate solution were then 





























a) After washing steps, membrane placed in hybridisation 
fluid 
b) Membrane placed in hybridisation bag 
c) Bag placed in radiograph cassette and X-ray sensitive films 
placed on top. This was left for a minimum of 6 hours 







added to the DNA side and the bag closed, making sure to avoid trapping bubbles of air. Excess 
solution was squeezed out and the edge of the bag was sealed. 
Detection of labelled telomeres was achieved by exposing the membrane to X-ray sensitive film. 
In a dark-room, under a red light, the hybridisation bag was placed flat in a radiograph cassette 
and x-ray sensitive film placed on top. The luminescence peaks over the first 6 hours so the 
membrane was left in the sealed dark box with the film for 6 hours, carefully avoiding shaking 
the box. The film was then developed and the highest intensity bar of each sample was 




The first two sets of rabbit samples that were processed had poor results. Identification of new 
bone growth was difficult as the new regenerate was a mix of fibrous tissue and immature 
bone. When the samples were processed, a large amount of fibrous material was included, 
which clogged the metal grinder and made it difficult to pulverise the bone. This led to 
decreased efficiency in decalcification, meaning that it had to be repeated further times than 
would otherwise have been necessary. 
The small quantity of actual bone 
harvested from the samples with 
low mineralisation led to very low 
yields of purified DNA. This meant 
that the subsequent steps of DNA 
digestion and telomere length assay 
were rendered inefficient and 
produced highly variable results, 
with at least 2 of the samples failing 
to show any result at all at chemo-
luminescence detection. 
The samples taken from the 
contralateral tibias of these rabbits 
were processed with adequate 
Figure 3.4a 
 



























a) Molecular weight marker 
b) Control markers (D17, SB, 3132) 





results, however. The expected yields of purified DNA were obtained and telomere length 
assay succeeding in producing detectable results. 
Each rabbit tibia yielded a total of 5 samples – a sample from the centre of regeneration and 2 
from either side. Each sample was further split into 3 samples in an attempt to reduce loss from 
error. This meant that for a single rabbit tibia, 15 samples were obtained and processed.  
A total of 6 rabbit tibias (3 
distraction and 3 control) were 
processed during the research 
period. This number required the 
cleaning/preparation of bone to be 
performed on 18 samples (5 from 
each distraction, 1 per control 
tibia), DNA elution/purification 
process to be carried out on 48 
samples (15 from each distraction 
tibia plus 1 per control tibia) and 
the electrophoresis/southern 
blot/chemoluminesence on 48 
samples in 3 batches (16 lanes per batch). 
A radiograph of a control sample with labelled markers is shown in figure 3.4a, demonstrating 
adequate DNA yield was obtained and that the process was successful. This control sample was 

























Example radiograph following chemoluminesence 
demonstrating molecular weight marker in leftmost 





The samples that were processed showed a diffuse spread of DNA fragments on detection, 
compared with the control, as shown in figure 3.4b. This may be due to a number of problems. 
Firstly, the low yield of DNA would not have provided enough DNA fragments for visible 
bands to develop. Secondly, the difficulties in preparing the bone may have limited the efficacy 
of the digestion process and hybridisation. 
 
As it was only possible to carry out the procedures on 2 rabbits at a time, there were large time 
intervals between obtaining sets of samples. After noting the immature state of the regenerate 
in the first pair of samples, radiographs were taken sequentially of each tibia to ensure the 
distraction was progressing well and adequate bone was consolidating. On examination of a 
further 2 samples, the radiographs showed immature regenerate and hence further time was 
allowed for consolidation following the end of the distraction period. 
 
Unfortunately, the increased time required for identification and preparation of samples meant 
that only the initial samples were processed by the end of the period of degree time, and hence 








Plans for Future Research
64 
 
Part 4.1 - Method for Measuring Telomere Lengths in Cortical and Cancellous Bone 
The method outlined above was adapted from 3 pathways to decalcify bone, purify the DNA 
from its cells and measure the length of the telomeres involved. In carrying out the literature 
review, no similar method was found to be described previously. If this method is reliable and 
repeatable, it may be useful in future research. 
To identify this, we plan to carry out the process on a number of samples and ascertain whether 
it is viable. If this is successful we hope to publish the technique as a manuscript. 
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Part 4.2 - Continuation of Current Research 
Due to the difficulties encountered in completing the laboratory work, only 3 of the rabbit 
samples have been fully processed so far. The other samples are still held in the -60℃ storage 
freezer in the Chancellor’s Building at the Edinburgh Royal Infirmary, awaiting processing. 
As the process of decalcification, DNA isolation and telomere length assay has been shown to 




Part 4.3 - Smoking, Osteoporosis and Telomere length 
I have also been looking at the relationship between smoking and telomere length and plan to 
investigate if there is a link between smoking, reduced telomere length and osteoporosis. 
Smoking has been long recognised as a major risk factor in many chronic diseases, including 
cancer, heart disease and respiratory disease, leading to 5 million deaths per annum, globally. 
Cigarette smoke is a complex mix of over 5 thousand different chemicals, including oxidants 
and free radicals. These, in combination with the increase in generation of reactive oxygen 
species, cause damage to lipids, proteins and DNA in cells throughout the smoker’s body.  
Clinical and epidemiological studies have shown that shorter mean telomere lengths in 
leukocytes are associated with cardiovascular disease, obesity, insulin resistance and dementia45. 
Oxidative stress and inflammation are known to accelerate telomere shortening and both are 
direct effects of cigarette smoking. Recent studies have shown a direct relationship between 
smoking and peripheral leukocyte telomere length, with significantly shorter telomeres in 
healthy individuals who smoked, compared with those who did not46. Telomere length was 
found to be approximately 5 base-pairs shorter per ‘pack-year’ when adjusted for age and other 
risk factors47. 
Previous research has established links between smoking and reduced telomere length in many 
tissues and diseases. There has been little study into whether or not smoking causes a decrease 
in telomere length in cells of the axial skeleton, or if there is a link between reduced telomere 
length and risk of osteoporosis. 
Information on smoking history is routinely gathered from patients when they enter hospital, 
either at the pre-assessment stage for elective operations or on clerk-in questioning, if emergent. 
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Discard material from femoral heads can be obtained following elective or post-traumatic 
arthroplasty. The mean telomere length in the discard material tissue can be measured and 
plotted against the smoking history to identify any trend. 
The severity of osteoporosis could also be ascertained if the patient has had, or is due to have, a 
DEXA scan. It may also be possible to obtain an assessment of bone density by taking 
radiographs of the bone section and comparing their x-ray penetration to a calibrated measure. 
This could be done by placing a metal wedge on the x-ray film with increasing steps of known 
density. This method is being used in ongoing research. 
For the research into smoking and osteoporosis, 2-3 cm3 samples of femoral neck cancellous 
bone will be obtained from trauma and elective arthroplasty patients. The samples taken will be 
part of discard material so will be covered under the ‘discard material’ ethics application, 
already in place in the unit.  
Once collected, the samples will be kept in a -60C freezer until the decalcification procedure can 
be carried out. Each sample will be split into 3 separate samples to be processed individually, to 
try to eliminate error and avoid loss from failed assay. 
A smoking history will be obtained from each patient as outlined above and follow them up to 
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Solution Constituents for DNA/Telomere Assays 
Isolation of Genomic DNA 
 
Before the isolation procedure was started, the necessary buffers were prepared as 
follows and stored at room temperature: 
Name Constituents 
Buffer ‘G2’ 800 nM guanidine HCL, 30nM Tris-Cl at pH 8.0, 30 nM EDTA at pH 8.0, 
5% Tween-20, 0.5% Triton X-100 
Buffer ‘QBT’  750 nM NaCl, 50 nM MOPS at pH 7.0, 15% isopropanol, 0.15% Triton X-
100 
Buffer ‘QC’ 1.0 M NaCl, 50 nM MOPS at pH 7.0, 15% isopropanol 
Buffer ‘GF’ 1.25 M NaCl, 50 nM Tris-Cl at pH 8.5, 15% isopropanol 
 
 
Telomere Length Assay (Taken from Roche TeloTAGGG Telomere Length Assay) 
 
Name Constituents 
TAE Buffer 0.04M Tris-acetate, 0.001 M EDTA, pH8 
HCl Solution 0.25M HCl 
Denaturation Solution 0.5M NaOH, 1.5M NaCl 
Neutralisation Solution 0.5M Tris-HCl, 3M NaCl, pH7.5 
20x SSC 3M NaCl, 0.3M Sodium Citrate, pH7.0 
2x SSC Dilute 20x SSC 1:10 with autoclaved, redistilled water 
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Name Constituents 
DIG Easy Hyb Granules provided with kit - reconstituted with 64ml 
autoclaved, redistilled water and incubated at 37℃. Pre-
warmed to 42℃ the night before use. 
Stringent Wash Buffer I 2x SSC, 0.1% SDS 
Stringent Wash Buffer II 0.2x SSC, 0.1% SDS 
Washing Buffer 1x Dilute 10x washing buffer (as provided with kit) 1:10 with 
autoclaved, distilled water 
Blocking Solution 1x Dilute 10x blocking buffer (as provided with kit) 1:10 with 
maleic acid buffer 1x (as prepared below) 
Maleic Acid Buffer 1x Dilute 10x maleic buffer (as provided with kit) 1:10 with 
autoclaved, distilled water 
Anti-DIG-AP working 
solution 
Anti-DIG-AP vial (as provided with kit) spun at 13000rpm for 
5 minutes then diluted with blocking solution 1x (as prepared 
above) at 1:10,000 (10µl in 10ml) 
Detection Buffer 1x Detection buffer 10x (as provided with kit) 1:10 with 




Animal License Details 
License number 60/3396  
Departmental license for animal handling 
Individual license held by Dr David Cottrell, who performed the procedures on the 
rabbits 
I did not carry out any procedures on live animal subjects 
 
